ABI Cites Applied Markets, New Instruments for 'Good' MS Quarter; Analyst Says Bruker 'Key Beneficiary' of Stimulus Funds

In an SEC filing, Life Tech repeated a forecast of zero growth to a 10 percent decline in mass specs for 2009. Separately, an analyst said Bruker's new MALDI-TOF/TOF could be a "small negative" for Life Tech.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.